Phase 2 N=39 Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men
Cortisol Resistance · Negative Feedback · ACTH
Primary: Proportion of Suppressors After Dexamethasone — 0; 1 Participants — p=0.4872
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=8 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
Mild Hypercortisolism
Primary: A1C Level — 6.2; 6.1375; 6.125 percentage of red blood cells
N/A N=21 Hypoglycemia and the Mineralocorticoid Receptor
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
N/A N=20 Protection Against Insulin Resistance in Obesity
Obesity · Insulin Resistance
Primary: Insulin Sensitivity — 273; 817 nmol/kg FFM/min /(µU/mL Insulin)
Phase 3 N=53 Prevention of Metabolic Complications of Glucocorticoid Excess
Iatrogenic Cushing Disease
Primary: CT Abdomen — 0.08; -0.03 ratio
Phase 3 N=94 Treatment for Endogenous Cushing's Syndrome
Endogenous Cushing's Syndrome
Primary: Normalization in Urinary Free Cortisol in Patients With Endogenous Cushing's Syndrome. — .30 proportion of subjects meeting endpoint — p=0.0154
Phase 2 N=8 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Phase 4 N=12 Eszopiclone Treatment & Cortisol Responsivity
Insomnia
Primary: Cortisol Response to the Dex/CRH Test Post-treatment (6 Weeks Oral Drug) — 108.98 nmol/L
Phase 2 N=19 Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults
Endocrine Disease · Diabetes
Primary: Change in Insulin Sensitivity Index — 1.49; 1.41 min-1·μU·ml-1 — p=0.60
Phase 4 N=66 Exploring the Effects of Corticosteroids on the Human Hippocampus
Hydrocortisone · Depression · Healthy Volunteers
Primary: Hippocampal Subfield Activation (Left Hemisphere) — -0.35; 0.03; -0.08; -0.07 Z-Score
Phase 1 N=38 Aldosterone and the Metabolic Syndrome
Metabolic Diseases · Diabetes Mellitus · Endocrine System Diseases
Primary: Plasma Insulin — 75.4; 50.1; 43.5; 114.0 uU/ml
Phase 2 N=35 Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's Syndrome
Primary: Percentage of Participants With One or More Adverse Events — 15; 18 Participants
N/A N=23 Stress and the Nervous System
Autonomic Nervous System · Baroreflex · Stress, Physiological
Primary: Cardiovagal Baroreflex Sensitivity (Modified Oxford Technique) — 17.75; 16.90; 14.42; 17.27 ms/mmHg
Phase 2 N=14 Real-time Adaptation to Changes in Insulin Sensitivity
Type 1 Diabetes Mellitus
Primary: Measurement of the Effectiveness of APD and FMPD/APD Intervention in Adapting to Reduced Insulin Sensitivity — 176; 195 mg/dl
Phase 4 N=60 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)
Adrenal Insufficiency
Primary: Change in Cognition After 10 Weeks of Treatment With a Low Dose of Hydrocortisone Compared to 10 Weeks of Treatment With a High Dose of Hydrocortisone. — -0.41; -0.42…
Phase 2 N=35 Insulin Resistance and Testosterone in Women
Insulin Resistance · Postmenopause
Primary: Percent Change in Free Testosterone (T) — -6.9; -35.8; 12.1 percent change
Phase 3 N=137 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
Phase 2 N=48 A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
Uncontrolled Hypertension
Primary: Number of Participants With Serum Total Cortisol Level Before and After Adrenocorticotropic Hormone (ACTH) Stimulation Test — 0; 0; 26; 15 Participants
N/A N=91 Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)
Post Traumatic Stress Disorder
Primary: Mean Baseline Startle Magnitude During Fear Conditioning — 48.401; 56.595; 115.778; 57.684 microvolts
N/A N=10 Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
Pre-diabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Insulin Sensitivity — 1835.4; 1846.0 ratio without units — p=.983
N/A N=58 Molecular Mechanisms of Exercise Benefits to Insulin Resistant People
Insulin Resistance · Obesity
Primary: Change in Muscle Strength — 0.37; -0.2 Ratio
Phase 2 N=15 Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
Anxiety Disorders
Primary: Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects — 1 Participants
Phase 3 N=4 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Cushing's Disease · Cushing's Syndrome
Primary: Number of Participants With Adverse Events — 4 participants
Phase 4 N=42 Endogenous Opioid Activity and Affective State in Insulin Resistant Women
Depression · Insulin Resistance · Metabolic Syndrome
Primary: Mu-opioid Receptor Binding Potential in Left Nucleus Accumbens, Resting State
Phase 2 N=14 Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
Phase 4 N=37 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Hyperglycemia · Diabetes Mellitus
Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35
N/A N=38 Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
Obesity · Insulin Resistance
Primary: Change From Baseline in Post-ischemic Dilatation — 9.6; 10.2; -1.2; -2.0 percent dilalation
Phase 2 N=6 Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes
Diabetes · Metabolic Syndrome · Insulin Resistance
Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale
Phase 3 N=64 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
Adrenal Insufficiency
Primary: Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma After Multiple Doses During Part A — 3962.0; 4879.6 hour*nanomole…